Evaluating Interventional Radiology for Cancer Pain Management

NCT07529314 | Not Yet Recruiting

• 1 other identifier: 69HCL25_1073
• Study Type: interventional
• Target: 125
• Locations: 0 countries
• Sites: N/A

Brief Summary

Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Nevertheless, recent studies indicate that the prevalence of pain in patients with locally advanced or metastatic cancer remains high. Cancer-related pain presents various characteristics, both in terms of timing (inflammatory and mechanical) and types (nociceptive, neuropathic, mixed, or visceral). This diversity in presentation and pathophysiology makes the condition complex, both in terms of symptom assessment and therapeutic management, requiring a multidisciplinary and often multimodal approach. In addition to pharmacological approaches, several non-pharmacological techniques are used for this purpose, as the interventional radiology (IR), so-called minimally invasive technique. The role of IR is becoming increasingly important in pain management, particularly in the context of a growing number of cancer survivors, improved survival in the metastatic setting and the limited effectiveness of opioids. These techniques include neurolysis, embolization, consolidation techniques, ablation, and percutaneous cervical cordotomy. The objective of the RI-Lief study is to evaluate the impact of interventional radiology on improving the quality of life of patients with locally advanced or metastatic cancer. As part of the study, interventional radiology will be included in the standard patient care. The only additional procedure introduced by the research is the administration of questionnaires.

Conditions

Locally Advanced Cancer; Metastatic Cancer

Keywords

Cancer; Pain

Outcome Measures

Primary Outcomes (1)

• Difference in pain intensity measured on a numerical scale before the interventional radiology procedure, and at 7 days, 1 month, and 3 months afterward.

  To evaluate the efficacy of interventional radiology for pain relief in improving pain intensity in patients with locally advanced or metastatic cancer.

  Baseline, 7 days, 1 month and 3 months after the radiology intervention.

Study Arms (1)

Self-reported questionnaires

OTHER

Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life : EORTC QLQ-C30 questionnaire ( (European Organisation for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) Core30 (C30))

Other: Self-reported questionnaires

Interventions

Self-reported questionnaires OTHER

Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life (EORTC QLQ-C30 questionnaire)

Self-reported questionnaires

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patient (age \> 18 years);
• Patient with locally advanced or metastatic cancer undergoing active management, including palliative care;
• Patient with a clinically estimated life expectancy of at least 3 months;
• Patient receiving treatment with chemotherapy, immunotherapy, targeted therapy, hormone therapy, or any other type of treatment for locally advanced or metastatic cancer;
• Patient undergoing an interventional radiology procedure for pain relief (including cases where pain relief is not the primary objective);
• Patient able to complete the proposed questionnaires.

You may not qualify if:

• Patient with cancer in remission;
• Patient with cured cancer;
• Patient under routine follow-up.

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

MeSH Terms

Conditions

Neoplasm Metastasis; Neoplasms; Pain

Condition Hierarchy (Ancestors)

Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neurologic Manifestations; Signs and Symptoms

Central Study Contacts

Guillaume ECONOMOS

CONTACT

04.78.86.10.99; guillaume.economos@chu-lyon.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 14, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: April 14, 2026

Record last verified: 2026-04